GlassScriptPhysician profile
Anthony Marino
NPI 1386630804
$10,315.44
in general payments reported to CMS, 2019-2025
40 companies · $2,210 in 2025
The $2,210 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,047 · 2020: $815 · 2021: $912 · 2022: $1,260 · 2023: $1,429 · 2024: $1,641 · 2025: $2,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,260 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,260.28 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,822.72 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,350.56 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Janssen Pharmaceuticals, INC | $1,111.45 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $965.31 | 2019-2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $563.89 | 2022-2025 | |
| Pfizer INC. | $494.76 | 2019-2025 | |
| Novo Nordisk INC | $492.95 | 2019-2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $451.81 | 2019-2025 | Jardiance |
| Amgen INC. | $442.05 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $303.83 | 2019-2025 | Verquvo |
| Lilly USA, LLC | $242.82 | 2019-2024 | Mounjaro |
| Heartflow, INC. | $229.22 | 2024-2025 | |
| Esperion Therapeutics, INC. | $205.23 | 2020-2025 | Nexletol |
| Abbott Laboratories | $153.87 | 2019-2025 | Aveir |
| Allergan, INC. | $153.01 | 2019-2020 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Marino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.